Obstet Gynecol Sci.  2015 Sep;58(5):397-400. 10.5468/ogs.2015.58.5.397.

Efficacy and safety of a 24-day regimen of drospirenone-containing combined oral contraceptive in Korean women

• Kim N
• Yoo HN
• Hyun HS
• Lee DY
• Yoon BK
• Choi DS

• KMID: 2058464
• DOI: http://doi.org/10.5468/ogs.2015.58.5.397

Abstract

This study assesses the efficacy and safety of a 24-day regimen of drospirenone-containing combined oral contraceptive, and demonstrates that it is an effective and safe option for contraception, releasing symptom of premenstrual dysphoric disorder and acne in Korean women.

Keyword

Contraceptives, oral, combined; Efficacy; Safety; Korea

MeSH Terms

Acne Vulgaris
Contraception
Contraceptives, Oral, Combined
Female
Humans
Korea
Contraceptives, Oral, Combined

Figure

• 

  Fig. 1 (A) Efficacy of Yaz for non-contraceptive benefits. (B) Compliance of Yaz by indication. PMDD, premenstrual dysphoric disorder.

Reference

1. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009; 339:b2890.

2. Van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009; 339:b2921.

3. Sitruk-Ware R, Nath A. The use of newer progestins for contraception. Contraception. 2010; 82:410–417.

4. Lee DY, Koo YA, Yoon BK, Choi D. Reproductive health characteristics of urban South Korean women. Gynecol Obstet Invest. 2010; 70:154–159.

5. Freeman EW. Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis. Psychoneuroendocrinology. 2003; 28:Suppl 3. 25–37.

6. Archer DF, Maheux R, DelConte A, O'Brien FB. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North american Levonorgestrel Study Group (NALSG). Am J Obstet Gynecol. 1999; 181(5 Pt 2):39–44.

7. Trussell J. Contraceptive failure in the United States. Contraception. 2011; 83:397–404.

8. O'Brien PM. The premenstrual syndrome. A review. J Reprod Med. 1985; 30:113–126.

9. Wichianpitaya J, Taneepanichskul S. A comparative efficacy of low-dose combined oral contraceptives containing desogestrel and drospirenone in premenstrual symptoms. Obstet Gynecol Int. 2013; 2013:487143.

10. Robinson JC, Plichta S, Weisman CS, Nathanson CA, Ensminger M. Dysmenorrhea and use of oral contraceptives in adolescent women attending a family planning clinic. Am J Obstet Gynecol. 1992; 166:578–583.

11. Leyden J, Shalita A, Hordinsky M, Swinyer L, Stanczyk FZ, Weber ME. Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: a randomized, placebo-controlled trial. J Am Acad Dermatol. 2002; 47:399–409.

12. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998; 179(3 Pt 1):577–582.

13. Bachmann G, Sulak PJ, Sampson-Landers C, Benda N, Marr J. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception. 2004; 70:191–198.